secwatch.observer — SEC 8-K summary
======================================

Issuer:     Citius Pharmaceuticals, Inc. (CTXR)
CIK:        0001506251
Form:       8-K
Filed at:   2024-04-05T23:59:59+00:00
Accession:  0001213900-24-030829
Event type: other_material
Sentiment:  neutral
Materiality: 0.25
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius extends CEO/EVP warrants to April 5, 2025; exercise would yield $2.3M
----------------------------------------------------------------------------

- Board approved one-year extension for 1,294,498 Investor Warrants held by CEO Leonard Mazur and EVP Myron Holubiak, exercise price $1.42 each.
- Also extended 240,130 Placement Agent Warrants held by H.C. Wainwright representatives, exercise price $1.9313 per share.
- Warrants were originally issued in April 2019 and previously extended to April 2024; no other warrants from that offering remain.
- Full exercise of all extended warrants would generate about $2.3 million in cash proceeds for the company.
- All other terms and conditions of the warrants remain unchanged.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506251/000121390024030829/0001213900-24-030829-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506251/000121390024030829/ea0203367-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-030829

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer